drugset / Trial / NCT06839664

A Study of HS-20094 in Chinese Adults With Overweight or Obesity

NCT06839664

Phase 3 Completed 604 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.

Timeline

Start
2024-11-16
Primary completion
2026-01-04
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Olatorepatide Protein / enzyme biologic 5 mg Subcutaneous
Subject Olatorepatide Protein / enzyme biologic 10 mg Subcutaneous
Subject Olatorepatide Protein / enzyme biologic 15 mg Subcutaneous

Indications